thalidomide has been researched along with Chromosomal Triplication in 19 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 5.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality." | 2.74 | Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. ( Abboud, CN; Blum, W; Byrd, JC; Fehniger, TA; Kefauver, C; Marcucci, G; Payton, JE; Vij, R, 2009) |
| "MDS with trisomy 8 has been observed in adult patients with Behçet syndrome with some cases developing prior to the clinical manifestations of the latter." | 2.44 | Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: an immunologic link to a karyotypic abnormality. ( Bolton-Maggs, P; Field, A; Moots, R; Salim, R; Thachil, JV, 2008) |
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 1.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (52.63) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Sakai, H | 1 |
| Miura, I | 1 |
| Arai, A | 1 |
| Wei, Q | 1 |
| Zhang, X | 1 |
| Peng, Y | 1 |
| Chen, K | 1 |
| Xu, S | 1 |
| Huang, X | 1 |
| Zhang, L | 1 |
| Xie, Q | 1 |
| He, Y | 1 |
| Li, Y | 1 |
| Chai, J | 1 |
| Harrison, SJ | 1 |
| Perrot, A | 1 |
| Alegre, A | 1 |
| Simpson, D | 1 |
| Wang, MC | 1 |
| Spencer, A | 1 |
| Delimpasi, S | 1 |
| Hulin, C | 1 |
| Sunami, K | 1 |
| Facon, T | 1 |
| Vlummens, P | 1 |
| Yong, K | 1 |
| Campana, F | 1 |
| Inchauspé, M | 1 |
| Macé, S | 1 |
| Risse, ML | 1 |
| van de Velde, H | 1 |
| Richardson, P | 1 |
| Mangiacavalli, S | 1 |
| Pochintesta, L | 1 |
| Cocito, F | 1 |
| Pompa, A | 1 |
| Bernasconi, P | 1 |
| Cazzola, M | 1 |
| Corso, A | 1 |
| Fehniger, TA | 1 |
| Byrd, JC | 1 |
| Marcucci, G | 1 |
| Abboud, CN | 1 |
| Kefauver, C | 1 |
| Payton, JE | 1 |
| Vij, R | 1 |
| Blum, W | 1 |
| Mesa, RA | 1 |
| Hanson, CA | 1 |
| Ketterling, RP | 1 |
| Schwager, S | 1 |
| Knudson, RA | 1 |
| Tefferi, A | 1 |
| Coutinho, R | 1 |
| Costa, D | 1 |
| Carrió, A | 1 |
| Muñoz, C | 1 |
| Vidal, A | 1 |
| Belkaid, M | 1 |
| Campo, E | 1 |
| Nomdedeu, B | 1 |
| Smetana, J | 1 |
| Berankova, K | 1 |
| Zaoralova, R | 1 |
| Nemec, P | 1 |
| Greslikova, H | 1 |
| Kupska, R | 1 |
| Mikulasova, A | 1 |
| Frohlich, J | 1 |
| Sevcikova, S | 1 |
| Zahradova, L | 1 |
| Krejci, M | 1 |
| Sandecka, V | 1 |
| Almasi, M | 1 |
| Kaisarova, P | 1 |
| Melicharova, H | 1 |
| Adam, Z | 1 |
| Penka, M | 1 |
| Jarkovsky, J | 1 |
| Jurczyszyn, A | 1 |
| Hajek, R | 1 |
| Kuglik, P | 1 |
| ZELLWEGER, H | 1 |
| HUFF, DS | 1 |
| ABBO, G | 1 |
| Thachil, JV | 1 |
| Salim, R | 1 |
| Field, A | 1 |
| Moots, R | 1 |
| Bolton-Maggs, P | 1 |
| Jörgensen, G | 3 |
| Shiono, H | 1 |
| Holt, SB | 1 |
| Kernis, MM | 1 |
| Terrahe, K | 1 |
| Schönenberg, H | 1 |
| Poznanski, AK | 1 |
| Garn, SM | 1 |
| Holt, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.[NCT00466895] | Phase 1 | 37 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities[NCT00546897] | Phase 2 | 48 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CRi = Defined as CR with the exception of neutropenia <1000/uL or thrombocytopenia <100,000/ul. (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 4 |
Cytogenetic complete remission (CRc): Only patients with an identified cytogenetic abnormality may receive this designation. Defines as a morphologic complete remission plus reversion to a normal karyotype (no clonal abnormalities detected in a minimum of 20 mitotic cells). (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 1 |
| Cohort 2 | 3 |
Duration of remission: Defined as the interval from the date complete remission is documented to the date of recurrence (NCT00546897)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Cohort 2 | 10 |
CRm = Defined as morphologic leukemia-free state, including <5% blasts in BM aspirate with marrow spicules and a count of > 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC > 1000/uL, platelet count >100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. There is no duration requirement for this designation. (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 3 |
Morphologic leukemia-free state: Defined as < 5% blasts on the BM aspirate with spicules and a count of > 200 nucleated cells and no blasts with Auer rods, and no persistent extramedullary disease. (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 1 |
| Cohort 2 | 10 |
Overall survival: Defined as the date of first dose of study drug to the date of death from any cause. (NCT00546897)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Cohort 2 | 4 |
Partial remission (PR): Requires that the criteria for complete remission be met with the following exceptions: decrease of >50% in the percentage of blasts to 5-25% in the BM aspirate. A value of < 5% blasts in BM with Auer rods is also considered a partial remission. (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 1 |
| Cohort 2 | 0 |
Progression-free survival (PFS) denotes the chances of staying free of disease progression for a group of individuals suffering from a cancer after a particular treatment. It is the percentage of individuals in the group whose disease is likely to remain stable (and not show signs of progression) after a specified duration of time. Progression-free survival rates are an indication of how effective a particular treatment is. (NCT00546897)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Cohort 2 | 2 |
This is determined only for patients achieving a complete remission. Defined as the interval from the date of first documentation of a leukemia free state to date of recurrence or death due to any cause. (NCT00546897)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Cohort 2 | 10 |
Toxicity will be scored using CTCAE Version 3.0 for toxicity and adverse event reporting (NCT00546897)
Timeframe: 4 weeks after last dose of study drug [median duration of therapy was 65 days (range, 3-413 days)]
| Intervention | participants (Number) |
|---|---|
| Cohort 1 | 1 |
| Cohort 2 | 8 |
"CRm = Defined as morphologic leukemia-free state, including <5% blasts in BM aspirate with marrow spicules and a count of > 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC > 1000/uL, platelet count >100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. There is no duration requirement for this designation.~CRi = Defined as CR with the exception of neutropenia <1000/uL or thrombocytopenia <100,000/ul.~Cytogenetic complete remission (CRc): Only patients with an identified cytogenetic abnormality may receive this designation. Defines as a morphologic complete remission plus reversion to a normal karyotype (no clonal abnormalities detected in a minimum of 20 mitotic cells)." (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) | ||
|---|---|---|---|
| CRm | CRi | CRc | |
| Cohort 1 | 0 | 0 | 1 |
| Cohort 2 | 3 | 4 | 3 |
"RR = as patients obtaining any response (CRm + CRc +CRi + PR).~CRm = Defined as morphologic leukemia-free state, including <5% blasts in BM aspirate with marrow spicules and a count of > 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC > 1000/uL, platelet count > 100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. There is no duration requirement for this designation.~CRc = Cytogenetic complete remission (CRc): Only patients with an identified cytogenetic abnormality may receive this designation. Defines as a morphologic complete remission plus reversion to a normal karyotype (no clonal abnormalities detected in a minimum of 20 mitotic cells).~Morphologic complete remission with incomplete blood count recovery (CRi): Defined as CR with the exception of neutropenia <1000/uL or thrombocytopenia <100,000/ul.~Partial remission (PR): Requires" (NCT00546897)
Timeframe: After 2 cycles of low dose lenalidomide (approximately Day 113 for Cohort 1 and approximately Day 104 for Cohort 2)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CRm | CRc | CRi | PR | |
| Cohort 1 | 0 | 1 | 0 | 1 |
| Cohort 2 | 3 | 3 | 4 | 0 |
4 reviews available for thalidomide and Chromosomal Triplication
| Article | Year |
|---|---|
Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: an immunologic link to a karyotypic abnormality.
Topics: Adolescent; Anemia, Refractory; Behcet Syndrome; Chromosomes, Human, Pair 8; Female; Humans; Immunol | 2008 |
[Human genetic aspects of inborn ear, nose, and throat diseases].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Acrocephalosyndactylia; Child, Preschool; Chro | 1985 |
[Diseases and dermatoglyphics].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Chromosome Aberrations; Chromo | 1970 |
Principles of teratology.
Topics: Abnormalities, Drug-Induced; Amniocentesis; Animals; Chromosome Aberrations; Chromosome Disorders; C | 1972 |
1 trial available for thalidomide and Chromosomal Triplication
| Article | Year |
|---|---|
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, A | 2009 |
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, A | 2009 |
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, A | 2009 |
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, A | 2009 |
14 other studies available for thalidomide and Chromosomal Triplication
| Article | Year |
|---|---|
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat | 2022 |
Successful treatment by thalidomide therapy of intestinal Behçet's disease associated with trisomy 8 myelodysplastic syndrome.
Topics: Behcet Syndrome; Chromosomes, Human, Pair 8; Female; Humans; Immunosuppressive Agents; Intestinal Di | 2021 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 13; Female; Humans; Lenalidomide; Leukemia, Myeloid, | 2009 |
Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic | 2010 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrat | 2013 |
PHOCOMELIA AND TRISOMY E.
Topics: Classification; Diagnosis; Ectromelia; Infant, Newborn; Thalidomide; Toxicology; Trisomy | 1965 |
[Abnormalities in the field of otorhinolaryngology. Genetic report].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Acrocephalosyndactylia; Chromosome Aberrations | 1972 |
[Malformations in otorhinolaryngology. Genetic report].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Chromosome Aberrations; Chromosome Diso | 1972 |
The significance of dermatoglyphics in medicine. A short survey and summary.
Topics: Abnormalities, Drug-Induced; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 13-15 | 1973 |
[Diagnosis of malformations of the ear and temporal bone].
Topics: Abducens Nerve; Abnormalities, Drug-Induced; Abnormalities, Multiple; Audiometry; Craniofacial Dysos | 1972 |
[Malformation syndrome and urinary organs].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Chromosomes, Human, 1 | 1971 |
The thumb in the congenital malformation syndromes.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Acrocephalosyndactylia; Anemia, Aplastic; Arm; | 1971 |